Evidence map›Paper›PMID 38181093›Full record

ArticleScience immunology2024

LITAF protects against pore-forming protein-induced cell death by promoting membrane repair.

Caroline Stefani, Anna M Bruchez, Mario G Rosasco, Anna E Yoshida, Kayla J Fasano, Paula F Levan, Alina Lorant, Nicholas W Hubbard, Andrew Oberst, Lynda M Stuart and 1 more

Open access · greenAbstract read
In one paragraph

Article in Science immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. ESCRT-III function in membrane fission and repair.Nature reviews. Molecular cell biology · 2026
    Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Caroline StefaniCenter for Systems Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, USA.ORCID 0000-0003-3420-432X
Anna M BruchezCenter for Systems Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, USA.ORCID 0000-0003-1695-5349
Mario G RosascoCenter for Systems Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, USA.ORCID 0000-0003-4419-1497
Anna E YoshidaCenter for Systems Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, USA.ORCID 0009-0001-3717-1992
Kayla J FasanoCenter for Systems Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, USA.ORCID 0000-0002-5802-8140
Paula F LevanCenter for Systems Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, USA.
Alina LorantCenter for Systems Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, USA.ORCID 0000-0002-1201-1618
Nicholas W HubbardDepartment of Immunology, University of Washington, Seattle, WA, USA.ORCID 0000-0002-6322-4840
Andrew OberstDepartment of Immunology, University of Washington, Seattle, WA, USA.ORCID 0000-0002-9500-7912
Lynda M StuartCenter for Systems Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, USA.
Adam Lacy-HulbertCenter for Systems Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, USA.ORCID 0000-0003-2162-0156
University of Washington · USBenaroya Research Institute

Funding

Identification of Host Drug Development Targets in Influenza Using Transposon MutagenesisR33AI119341 · NIAID · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI LACY-HULBERT, ADAM · 2017 to 2019
$1.5M
Recognizing Virulent PathogensR01GM102482 · NIGMS · MASSACHUSETTS GENERAL HOSPITAL · PI STUART, LYNDA · 2013 to 2016
$1.3M
LITAF regulation of cell death and inflammatory responsesR56AI168995 · NIAID · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI LACY-HULBERT, ADAM · 2023 to 2023
$300k
NIAID NIH HHS R33 AI119341NIAID NIH HHS R56 AI168995NIGMS NIH HHS R01 GM102482
6 · The paper itself

Abstract

Pore-forming toxins (PFTs) are the largest class of bacterial toxins and contribute to virulence by triggering host cell death. Vertebrates also express endogenous pore-forming proteins that induce cell death as part of host defense. To mitigate damage and promote survival, cells mobilize membrane repair mechanisms to neutralize and counteract pores, but how these pathways are activated is poorly understood. Here, we use a transposon-based gene activation screen to discover pathways that counteract the cytotoxicity of the archetypal PFT

Indexed as

Bacterial ToxinsPyroptosisAnimalsCell DeathCell MembraneEndosomesBacterial Toxins

Identifiers

PMID38181093
PMCPMC11883904
OpenAlexW4390604144

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.